Organization | Biomedical Research Institute of New Mexico

Biomedical Research Institute of New Mexico Report issue

Academic/Hospital Phase 3 Phase 4

Organization Overview

First Clinical Trial

2009

NCT00945295

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2022

Timeline

NOW

Now

Alternative names

Biomedical Research Institute of New Mexico | JoAnn Harnar

Active Ingredients

Drugs in Phase 4 Trials (5)

exenatide (byetta) (1 trial)

insulin glargine (toujeo) (1 trial)

insulin human (humulin) (1 trial)

phentermine (wyamine) (1 trial)

sitagliptin (januvia) (1 trial)

Drugs in Phase 3 Trials (1)

testosterone (delatestryl) (1 trial)

Drugs in Other Trials (1)

rimabotulinumtoxinB (Myobloc) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Hypogonadism (Phase 3)

Overview

Highest Phase: Phase 4
# of Trials: 4
# of Trial APIs: 7